Delivery Order SPE2DR25D1205-SPE2DR26F0ZU5
- Not listed
- The Defense Logistics Agency (DLA) awarded a $3,836.00 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 120 tablets of Nubeqa 300 mg, with an ultimate completion date of February 4, 2026. This non-set-aside award was issued on January 13, 2026, with performance to be completed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc. (doing business as AmerisourceBergen), is a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $3,836.00 to AmerisourceBergen Drug Corp for the supply of Nubeqa 300 mg tablets (120 count) with a completion date of January 29, 2026. This non-set-aside, competitively awarded contract utilizes a firm fixed-price structure and represents a task order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The prime contractor, operating from its corporate office in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $7,672 firm fixed price delivery order to AmerisourceBergen Drug Corp for 120 tablets of Nubeqa 300 mg, with a completion date of January 22, 2026. This non-set-aside competitive award was issued on December 30, 2025, and represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply framework with the agency. The work will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,836.00 to AmerisourceBergen Drug Corp for 120 tablets of Nubeqa 300 mg, a pharmaceutical product, with an ultimate completion date of December 17, 2025. This is a competitively awarded, firm fixed-price delivery order with no set-aside designation, and performance will take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $15,283.96 for 120 tablets of Nubeqa 300 mg on June 18, 2025, with an ultimate completion date of July 11, 2025. This is a firm fixed-price, non-set-aside contract with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $3,640.00 to AmerisourceBergen Drug Corp for 120 tablets of Nubeqa 300 mg, a pharmaceutical product, with an ultimate completion date of September 22, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and specifies Conshohocken, Pennsylvania as the place of performance, which aligns with AmerisourceBergen's corporate headquarters location. This delivery order is issued under...
- The Defense Logistics Agency awarded a $3,836.00 delivery order to AmerisourceBergen Drug Corp for 120 tablets of Nubeqa 300 mg, a pharmaceutical product used in oncology treatment. The contract is a firm fixed price delivery order with an ultimate completion date of December 29, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs across...
- The Defense Logistics Agency awarded a delivery order valued at $3,640 to AmerisourceBergen Drug Corp for the supply of Nubeqa 300 mg tablets (120 count) on September 23, 2025, with an ultimate completion date of October 15, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $14,560 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 120 tablets of Nubeqa 300 mg, with an ultimate completion date of October 17, 2025. This is a non-set-aside competitive award issued as a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be performed and delivered from the contractor's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $3,836.00 to AmerisourceBergen Drug Corp for the supply of NUBEQA 300 mg tablets (120-count units) with an ultimate completion date of February 2, 2026. This non-set-aside, competitively awarded contract utilizes firm fixed-price pricing and is being performed at the awardee's location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop...
- SPE2DR25D1205Indefinite Delivery Contract
- SPE2DR25D1205-SPE2DR26F0ZU5Delivery Order
The Defense Logistics Agency awarded a $3,836.00 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 120 tablets of Nubeqa 300 mg, with an ultimate completion date of February 3, 2026. This non-set-aside competitive award is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen is a subsidiary of Cencora, Inc., a major pharmaceutical distributor serving federal healthcare systems, particularly the Department of Defense and military treatment facilities. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with the DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. This comprehensive IDC enables the contractor to supply a broad range of pharmaceutical products and medical supplies globally to support military healthcare programs, including specialty medications, brand-name and generic drugs, vaccines, and medical devices. Nubeqa is an oncology medication used in prostate cancer treatment, reflecting the contractor's role in delivering critical pharmaceutical commodities across multiple therapeutic domains to federal medical institutions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.8k | 1/11/26 |